 | • レポートコード：MRC2301D009 • 出版社/出版日：Transparency Market Research / 2022年11月15日 • レポート形態：英文、PDF、233ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の市場調査書では、世界の動物用薬物調剤市場について調査・分析を行い、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、製品別（抗感染薬、抗炎症薬、中枢神経作用薬、消化器官用薬、その他）分析、動物種類別（コンパニオン動物、家畜）分析、剤形別（カプセル、溶液、粉末、懸濁液、その他）分析、投与経路別（経口、注射剤、外用剤、直腸投与、接眼）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの内容を整理しました。並びに、当書に掲載されている企業情報には、Wedgewood Pharmacy、Triangle Compounding Pharmacy、Davis Islands Pharmacy、Custom Med Compounding Pharmacy、Central Compounding Center South、Wellness Pharmacy of Cary、Caringbah Compounding Pharmacy、Millers Pharmacy, Smith's Pharmacy、Specialist Compounding Pharmacy Pte Ltd.、Tache Pharmacyなどが含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・世界の動物用薬物調剤市場規模：製品別 - 抗感染薬の市場規模 - 抗炎症薬の市場規模 - 中枢神経作用薬の市場規模 - 消化器官用薬の市場規模 - その他動物用薬物調剤の市場規模 ・世界の動物用薬物調剤市場規模：動物種類別 - コンパニオン動物における市場規模 - 家畜における市場規模 ・世界の動物用薬物調剤市場規模：剤形別 - カプセル状動物用薬物調剤の市場規模 - 溶液状動物用薬物調剤の市場規模 - 粉末状動物用薬物調剤の市場規模 - 懸濁液状動物用薬物調剤の市場規模 - その他動物用薬物調剤の市場規模 ・世界の動物用薬物調剤市場規模：投与経路別 - 経口における市場規模 - 注射剤における市場規模 - 外用剤における市場規模 - 直腸投与における市場規模 - 接眼における市場規模 ・世界の動物用薬物調剤市場規模：地域別 - 北米の動物用薬物調剤市場規模 - ヨーロッパの動物用薬物調剤市場規模 - アジア太平洋の動物用薬物調剤市場規模 - 中南米の動物用薬物調剤市場規模 - 中東・アフリカの動物用薬物調剤市場規模 ・競争状況 |
Animal Drug Compounding Market – Scope of Report
TMR’s report on the global animal drug compounding market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global animal drug compounding market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global animal drug compounding market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the animal drug compounding market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global animal drug compounding market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global animal drug compounding market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global animal drug compounding market.
The report delves into the competitive landscape of the global animal drug compounding market. Key players operating in the global animal drug compounding market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global animal drug compounding market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market animal drug compounding.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Animal Drug Compounding Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Animal Drug Compounding Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Technological Advancements
5.2. Regulatory Scenario by Region/globally
5.3. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Animal Drug Compounding Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Anti-invectives
6.3.1.1. Metranidazole
6.3.1.2. Ketaconazole
6.3.1.3. Other Anti invectives
6.3.2. Anti-inflammatory
6.3.2.1. Prednisolone
6.3.2.2. Tramadol
6.3.2.3. Others
6.3.3. CNS Agents
6.3.3.1. Potassium bromide
6.3.3.2. Gabapentin
6.3.3.3. Other CNS agents
6.3.4. GI Drugs
6.3.4.1. Apomorphine
6.3.4.2. Ursodiol
6.3.4.3. Cisapride
6.3.4.4. Other GI Drugs
6.3.5. Others
6.4. Market Attractiveness Analysis, by Product
7. Global Animal Drug Compounding Market Analysis and Forecast, by Animal Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Animal Type, 2017–2031
7.3.1. Companion Animal
7.3.1.1. Dogs
7.3.1.2. Cats
7.3.1.3. Others
7.3.2. Live Stock
7.4. Market Attractiveness Analysis, by Animal Type
8. Global Animal Drug Compounding Market Analysis and Forecast, by Dosage Form
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Dosage Form, 2017–2031
8.3.1. Capsules
8.3.2. Solutions
8.3.3. Powders
8.3.4. Suspension
8.3.5. Others
8.4. Market Attractiveness Analysis, by Dosage Form
9. Global Animal Drug Compounding Market Analysis and Forecast, by Route of Administration
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Route of Administration, 2017–2031
9.3.1. Oral
9.3.2. Injectable
9.3.3. Topical
9.3.4. Rectal
9.3.5. Ocular
9.4. Market Attractiveness Analysis, by Route of Administration
10. Global Animal Drug Compounding Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Animal Drug Compounding Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. Anti-infectives
11.2.1.1. Metranidazole
11.2.1.2. Ketaconazole
11.2.1.3. Other Anti-infectives
11.2.2. Anti-inflammatory
11.2.2.1. Prednisolone
11.2.2.2. Tramadol
11.2.2.3. Others
11.2.3. CNS Agents
11.2.3.1. Potassium bromide
11.2.3.2. Gabapentin
11.2.3.3. Other CNS agents
11.2.4. GI Drugs
11.2.4.1. Apomorphine
11.2.4.2. Ursodiol
11.2.4.3. Cisapride
11.2.4.4. Other GI Drugs
11.2.5. Others
11.3. Market Value Forecast, by Animal Type, 2017–2031
11.3.1. Companion Animal
11.3.1.1. Dogs
11.3.1.2. Cats
11.3.1.3. Others
11.3.2. Live Stock
11.4. Market Value Forecast, by Dosage Form, 2017–2031
11.4.1. Capsules
11.4.2. Solutions
11.4.3. Powders
11.4.4. Suspension
11.4.5. Others
11.5. Market Value Forecast, by Route of Administration, 2017–2031
11.5.1. Oral
11.5.2. Injectable
11.5.3. Topical
11.5.4. Rectal
11.5.5. Ocular
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Animal Type
11.7.3. By Dosage Form
11.7.4. By Route of Administration
11.7.5. By Country
12. Europe Animal Drug Compounding Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2031
12.2.1. Anti-infectives
12.2.1.1. Metranidazole
12.2.1.2. Ketaconazole
12.2.1.3. Other Anti-infectives
12.2.2. Anti-inflammatory
12.2.2.1. Prednisolone
12.2.2.2. Tramadol
12.2.2.3. Others
12.2.3. CNS Agents
12.2.3.1. Potassium bromide
12.2.3.2. Gabapentin
12.2.3.3. Other CNS agents
12.2.4. GI Drugs
12.2.4.1. Apomorphine
12.2.4.2. Ursodiol
12.2.4.3. Cisapride
12.2.4.4. Other GI Drugs
12.2.5. Others
12.3. Market Value Forecast, by Animal Type, 2017–2031
12.3.1. Companion Animal
12.3.1.1. Dogs
12.3.1.2. Cats
12.3.1.3. Others
12.3.2. Live Stock
12.4. Market Value Forecast, by Dosage Form, 2017–2031
12.4.1. Capsules
12.4.2. Solutions
12.4.3. Powders
12.4.4. Suspension
12.4.5. Others
12.5. Market Value Forecast, by Route of Administration, 2017–2031
12.5.1. Oral
12.5.2. Injectable
12.5.3. Topical
12.5.4. Rectal
12.5.5. Ocular
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Animal Type
12.7.3. By Dosage Form
12.7.4. By Route of Administration
12.7.5. By Country/Sub-region
13. Asia Pacific Animal Drug Compounding Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2031
13.2.1. Anti-infectives
13.2.1.1. Metranidazole
13.2.1.2. Ketaconazole
13.2.1.3. Other Anti-infectives
13.2.2. Anti-inflammatory
13.2.2.1. Prednisolone
13.2.2.2. Tramadol
13.2.2.3. Others
13.2.3. CNS Agents
13.2.3.1. Potassium bromide
13.2.3.2. Gabapentin
13.2.3.3. Other CNS agents
13.2.4. GI Drugs
13.2.4.1. Apomorphine
13.2.4.2. Ursodiol
13.2.4.3. Cisapride
13.2.4.4. Other GI Drugs
13.2.5. Others
13.3. Market Value Forecast, by Animal Type, 2017–2031
13.3.1. Companion Animal
13.3.1.1. Dogs
13.3.1.2. Cats
13.3.1.3. Others
13.3.2. Live Stock
13.4. Market Value Forecast, by Dosage Form, 2017–2031
13.4.1. Capsules
13.4.2. Solutions
13.4.3. Powders
13.4.4. Suspension
13.4.5. Others
13.5. Market Value Forecast, by Route of Administration, 2017–2031
13.5.1. Oral
13.5.2. Injectable
13.5.3. Topical
13.5.4. Rectal
13.5.5. Ocular
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Animal Type
13.7.3. By Dosage Form
13.7.4. By Route of Administration
13.7.5. By Country/Sub-region
14. Latin America Animal Drug Compounding Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017–2031
14.2.1. Anti-infectives
14.2.1.1. Metranidazole
14.2.1.2. Ketaconazole
14.2.1.3. Other Anti-infectives
14.2.2. Anti-inflammatory
14.2.2.1. Prednisolone
14.2.2.2. Tramadol
14.2.2.3. Other Anti-inflammatory
14.2.3. CNS Agents
14.2.3.1. Potassium bromide
14.2.3.2. Gabapentin
14.2.3.3. Other CNS agents
14.2.4. GI Drugs
14.2.4.1. Apomorphine
14.2.4.2. Ursodiol
14.2.4.3. Cisapride
14.2.4.4. Other GI Drugs
14.2.5. Others
14.3. Market Value Forecast, by Animal Type, 2017–2031
14.3.1. Companion Animal
14.3.1.1. Dogs
14.3.1.2. Cats
14.3.1.3. Others
14.3.2. Live Stock
14.4. Market Value Forecast, by Dosage Form, 2017–2031
14.4.1. Capsules
14.4.2. Solutions
14.4.3. Powders
14.4.4. Suspension
14.4.5. Others
14.5. Market Value Forecast, by Route of Administration, 2017–2031
14.5.1. Oral
14.5.2. Injectable
14.5.3. Topical
14.5.4. Rectal
14.5.5. Ocular
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Animal Type
14.7.3. By Dosage Form
14.7.4. By Route of Administration
14.7.5. By Country/Sub-region
15. Middle East & Africa Animal Drug Compounding Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product, 2017–2031
15.2.1. Anti-infectives
15.2.1.1. Metranidazole
15.2.1.2. Ketaconazole
15.2.1.3. Other Anti-infectives
15.2.2. Anti-inflammatory
15.2.2.1. Prednisolone
15.2.2.2. Tramadol
15.2.2.3. Other Anti-inflammatory
15.2.3. CNS Agents
15.2.3.1. Potassium bromide
15.2.3.2. Gabapentin
15.2.3.3. Other CNS agents
15.2.4. GI Drugs
15.2.4.1. Apomorphine
15.2.4.2. Ursodiol
15.2.4.3. Cisapride
15.2.4.4. Other GI Drugs
15.2.5. Others
15.3. Market Value Forecast, by Animal Type, 2017–2031
15.3.1. Companion Animal
15.3.1.1. Dogs
15.3.1.2. Cats
15.3.1.3. Others
15.3.2. Live Stock
15.4. Market Value Forecast, by Dosage Form, 2017–2031
15.4.1. Capsules
15.4.2. Solutions
15.4.3. Powders
15.4.4. Suspension
15.4.5. Others
15.5. Market Value Forecast, by Route of Administration, 2017–2031
15.5.1. Oral
15.5.2. Injectable
15.5.3. Topical
15.5.4. Rectal
15.5.5. Ocular
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Country
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product
15.7.2. By Animal Type
15.7.3. By Dosage Form
15.7.4. By Route of Administration
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2021
16.3. Company Profiles
16.3.1. Wedgewood Pharmacy
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Company Financials
16.3.1.3. Growth Strategies
16.3.1.4. SWOT Analysis
16.3.2. Triangle Compounding Pharmacy
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Company Financials
16.3.2.3. Growth Strategies
16.3.2.4. SWOT Analysis
16.3.3. Davis Islands Pharmacy
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Company Financials
16.3.3.3. Growth Strategies
16.3.3.4. SWOT Analysis
16.3.4. Custom Med Compounding Pharmacy
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Company Financials
16.3.4.3. Growth Strategies
16.3.4.4. SWOT Analysis
16.3.5. Central Compounding Center South
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Company Financials
16.3.5.3. Growth Strategies
16.3.5.4. SWOT Analysis
16.3.6. Wellness Pharmacy of Cary
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Company Financials
16.3.6.3. Growth Strategies
16.3.6.4. SWOT Analysis
16.3.7. Caringbah Compounding Pharmacy
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Company Financials
16.3.7.3. Growth Strategies
16.3.7.4. SWOT Analysis
16.3.8. Millers Pharmacy
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Company Financials
16.3.8.3. Growth Strategies
16.3.8.4. SWOT Analysis
16.3.9. Smith’s Pharmacy
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Company Financials
16.3.9.3. Growth Strategies
16.3.9.4. SWOT Analysis
16.3.10. Specialist Compounding Pharmacy Pte Ltd.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Company Financials
16.3.10.3. Growth Strategies
16.3.10.4. SWOT Analysis
16.3.11. Tache Pharmacy
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Company Financials
16.3.11.3. Growth Strategies
16.3.11.4. SWOT Analysis